Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has introduced Memary 5mg, 10mg and 20mg Tablets, a medication for the treatment of moderate to severe Alzheimer's disease (AD), in Japan.
Subscribe to our email newsletter
Memary, an N-methyl-D-aspartate (NMDA) receptor antagonist, is the generic version of Memantine Hydrochloride, which was licensed from Merz Pharmaceuticals.
Daiichi Sankyo has obtained the Japanese approval to manufacture and market Memary 5mg, 10mg and 20mg Tablets on 21 January 2011.
The drug was approved for use in the treatment of patients with AD by the European EMEA in 2002 and by the US Food and Drug Administration in 2003.